CLOs on the Move

Haematologic Technologies

www.haemtech.com

 
A large molecule CRO combining world-class protein chemistry expertise, integrated large molecule analytical services, and coagulation reagents for biopharma R&D.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Fluke Biomedical

Fluke Biomedical Corp. is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagenode

Diagenode is a leading global provider of complete solutions for epigenetics research, biological sample preparation, and diagnostics assays based in Liege, Belgium and NJ, USA. The company has developed a comprehensive approach to gain new insights into epigenetics studies. The company offers innovative Bioruptor® shearing and IP-Star® automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company`s latest innovations include a unique, full automation system, the industry`s most validated antibodies, the Megaruptor shearing system for long fragment generation in sequencing, and epigenetics assay services.

Response Biomedical Corporation

Response Biomedical Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Kira Pharmaceuticals

Kira Pharmaceuticals is pioneering complement drug discovery to deliver transformative therapies for people with complement-mediated diseases

Beigene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.